Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP, highlights current challenges surrounding the incorporation of biosimilars, the future role of phase 3 clinical studies, the importance of biosimilars to the healthcare system, and the role of the FDA in educating stakeholders.
March 20, 2019
View Text Version
x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.